Seeking Alpha

Perrigo (PRGO +0.2%) announces that it nabbed final FDA approval for Desloratadine. The product...

Perrigo (PRGO +0.2%) announces that it nabbed final FDA approval for Desloratadine. The product - set for commercial launch in July 2012 - is a generic version of Schering-Plough's Clarinex allergy relief treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|